Posts

Cullinan and Taiho Report Phase III Win for Zipalertinib–Chemotherapy Combo in First-Line EGFR Exon 20 Insertion–Mutant NSCLC

on

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

on

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN‑001 in Frontline Ovarian Cancer, Overcoming Historical IL‑12 Safety Barriers

on

Globalisation 2.0 | Henlius Completes First Patient Dosed in China for MRCT of pimurutamab (HLX07) Plus serplulimab, Accelerating Global Development

on

Merck's ADC sac‑TMT gets its first global Phase 3 win ahead of schedule

on

Garda Therapeutics Acquires Assertio and Rolvedon in $125.1M Deal

on

Updated Efficacy Data of Ivonescimab Plus Chemotherapy as First-Line Treatment for TNBC at ESMO IO 2025

on

Ono's BMS-Partnered Oral Gastric Cancer Drug Meets Primary Endpoint in Phase 2 Trial

on

AstraZeneca and Daiichi Sankyo Report Landmark Results for Datroway in Triple-Negative Breast Cancer

on

BioNTech and BMS Announce First Global Data for PD-L1xVEGF Bispecific in Small Cell Lung Cancer, Set Phase 3 Dose

on

AstraZeneca Escalates EGFR Lung Cancer Rivalry with J&J: Tagrisso Combo Posts Survival Win

on

ImmuneOnco and Instil Bio's PD-L1xVEGF Bispecific Antibody Shows Promising Results in Phase 2 Lung Cancer Trial

on

AstraZeneca Highlights Survival Benefit for Tagrisso Combo Amid Competition in Lung Cancer

on

Akeso, Summit's PD-1/VEGF bispecific records another pivotal study win in NSCLC

on

BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific

on